KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Novavax (NVAX) Net Income: 2010-2025

Historic Net Income for Novavax (NVAX) over the last 16 years, with Sep 2025 value amounting to -$202.4 million.

  • Novavax's Net Income fell 66.84% to -$202.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $341.7 million, marking a year-over-year increase of 219.97%. This contributed to the annual value of -$187.5 million for FY2024, which is 65.60% up from last year.
  • According to the latest figures from Q3 2025, Novavax's Net Income is -$202.4 million, which was down 290.01% from $106.5 million recorded in Q2 2025.
  • In the past 5 years, Novavax's Net Income ranged from a high of $518.6 million in Q1 2025 and a low of -$846.3 million during Q4 2021.
  • Moreover, its 3-year median value for Net Income was -$121.3 million (2024), whereas its average is -$28.2 million.
  • As far as peak fluctuations go, Novavax's Net Income plummeted by 1,910.83% in 2021, and later spiked by 451.51% in 2025.
  • Novavax's Net Income (Quarterly) stood at -$846.3 million in 2021, then surged by 78.46% to -$182.2 million in 2022, then grew by 2.12% to -$178.4 million in 2023, then soared by 54.58% to -$81.0 million in 2024, then slumped by 66.84% to -$202.4 million in 2025.
  • Its Net Income stands at -$202.4 million for Q3 2025, versus $106.5 million for Q2 2025 and $518.6 million for Q1 2025.